focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks KUMS looking through now . . .
Welcome Ant. Just look at previous posting & you will see excellent postings. Best to be in now & wait.
Will be new to FAST when I do I buy in over the next week. love the idea of what they're aiming to do with EB and phase 3 trials in 2016 and huge market for Orphan drugs not to mention if they do get to list on the NASDAQ eventually - the U.S love these type of companies. This is all what I think but I'd like to know everyone else's view on th recent news?? Thanks and GLA Ant
Good info GFD....Thanks If they can generate sales in Europe and get FDA approval in USA all should be rosy...management team is a major plus as they will know the ropes.. Have about 8g invested so I'll let it ride
Plenty of buys under the mid price, so listed as sells. Early Bird: I see your link has been censored but it is for the share prophets website. I don't care for TW but at least he has has put his money where his mouth is. "We should say that FIML ( owned by Tom Winnifrith's family trust) has invested a material sum in the placing at 3p (24p post consolidation) and we see further upside in this stock based on our conversations with management."
http://www.*************.com/views/19788/fastnet-a-cracking-rto-completed-we-are-well-up-on-this-share-tip-more-to-go
Yeah saw that on Imlan only marketed in Germany apparently. Am I right that Birkin has already invested over 50 mil to get Episalvan to this stage?
Ok got my info from Sea in an earlier post. Little concerned that there are too many shares outstanding for a start up with no revenue and more dilution down the pipeline.
I am in no way major investor just small pi but can see upside for me its not always about the horse but the Jockey if you get my drift? good BOD Can make all the difference Time will tell here but no reason why not dyor as ever
If they are saying that 24 pence will be the new share issue price and that the current acquisition price is 3 pence does that imply a 1 for 8 reverse split for current Fastnet shareholders?
Watch & not what! correction.
Did say that in Dec 15 when we were c2.30p. What this one as we start getting the news.
May see the real rise today as people realise the huge potential
on AIM with a phase 3 approved drug with EU approval ready for marketing at £50M MC... the rest are only just starting lengthy phase 3 trials that are years away... The next set of phase 3 trials here are for Episalvan approval in treatment of the rare disease "EB" for which there is currently no effective treatment hence the huge opportunity. The fact that Episalvan is already Phase 3 approved for partial thickness wounds means its trials for EB (starting in H2) will not be lengthy and very likely to be approved. So we can soon start marketing Episalvan as a treatment for partial thickness wounds on the side to this huge potential game changing EB trial. If approved then its a total game changer and this will unleash the huge £100M+ per annum cashflows and therefore warrant £1b+ MC If you look at the directors involved and the amount they have put on the line here (buying 30% of the co.) join the dots you have something really very exciting here.
€10,000,000 on receipt of first marketing approval by the EMA of Episalvan (which is payabe on Admission, as this has been received); •e ither (1) €5,000,000 once net exfactory sales of Episalvan have been at least €100,000 or (ii) if no commercial sales are made within 24 months of EMA first marketing approval €2,000,000 24 months after receipt of such approval and €3,000,000 following the first commercial sale; • €10,000,000 once net exfactory sales/net revenue in any calendar year exceed €50,000,000; • €15,000,000 once net exfactory sales/net revenue in any calendar year exceed €100,000,000; • €10,000,000 on receipt of marketing approval by the EMA or FDA of the orphan drug product containing betulin as its API for the treatment of Epidermolysis Bullosa; So its 10m euro payable on the approval and the rest of the royalties relate to cashflow which -by the way- is serious serious cashflow of 100 million euros per anum. Think about it. Once we are achieveing 100m euros per anum cashflow what is a tiny 10m euro payment? Our market cap by then will be over £1billion I'm very excited.
From pg 113 Birken acquisition Amryt signed a conditional SPA to acquire Birken on 16 October 2015 (the “Birken SPA”). Birken is 99.7% owned by the Software AG Stiftung, a charitable foundation founded and controlled by Dr Peter Schnell, a German billionaire. Completion under the Birken SPA is conditional, amongst other things, on Amryt being acquired by Fastnet, admission of the enlarged group to trading on AIM and the associated share placing generating net proceeds in excess of €5 million (“Share Placing”). Under the terms of the Birken SPA the shareholders in Birken receive: • An initial payment of €1 million (see note 9); • €150,000 on Completion; • Milestone payments totaling up to €50 million payable on achieving certain regulatory Interesting so Birken to receive 50m euros on just getting Regulatory Approval http://www.fastnetequity.com/~/media/Files/F/Fastnet-Oil-and-Gas/circulars/amryt-admission-document.pdf
Can't help but think some that have sold or those who have not bought in have not read the RNS properly. Massive gains from these levels. management could not get any stronger : The New Board has a broad network of industry contacts. This is exemplified by the experienced advisers engaged by Amryt while it conducted its due diligence on Birken and Som, whose experience includes Pfizer and the US FDA. These contacts should also provide the Enlarged Group with access to additional prospective projects going forward and ensure a continuous pipeline of opportunities and further potential acquisitions, which will be assessed as they arise.
That's the game changer mate... if we get Episalvan approved for EB then this is heading to the moon as currently no drug out there that deals with this rare disease and its essentially $1.5b per anum cashflow for us. That's buyout teritory by the major players for a lofty sum. We have Episalvan already EU approved for skin thickness wound treatment which will get revenue started on this, these Phase III trials for EB however are the real game changer. V v exciting.
Significant market upside in Epidermolysis Bullosa ("EB") - Episalvan has successfully completed a Phase IIa study in ten EB patients (data from 12 wounds), in which Episalvan demonstrated significantly faster healing over 14 days of treatment for recent wounds and 28 days of treatment for chronic wounds compared with standard of care therapy. The New Board intends to pursue a label extension for Episalvan in Europe and seek FDA approval for Episalvan to treat EB in the US. The New Board estimates the global EB market to be worth approximately US$1.5 billion per annum.
Better buying now because come 19 April you will struggle to buy in at 24p as 67% of shares not available ------ Following Admission and the implementation of the Proposals, the Vendors, taking into account their holdings in Existing Ordinary Shares and following their participation in the Placing, will hold interests in 139,579,380 New Ordinary Shares representing 67.0 per cent. of the Enlarged Share Capital.
highly experienced management team - The New Board and senior management is comprised of experienced industry participants including: · Harry Stratford, Chairman, is the founder of Shire plc, now a FTSE 100 biopharmaceutical company, and ProStrakan Group plc · Joseph Wiley, CEO, has over 20 years' experience in healthcare investment and pharmaceutical operational roles · Rory Nealon, CFO and COO, has spent the last 13 years as both CFO and then COO of Trinity Biotech PLC, a NASDAQ listed company · Michele Bellandi, CCO, is the former Head of Commercial Europe for Shire AG International and has held senior marketing roles at Serono and Eli Lilly · Ray Stafford, a Non-Executive Director, previously EVP of Global Marketing for Forest Laboratories which was listed on NYSE prior to being acquired for approximately US$28 billion · James Culverwell, a Non-Executive Director, previously head of European pharmaceutical equity research at Merrill Lynch in London until 2005.
http://www.fastnetequity.com/~/media/Files/F/Fastnet-Oil-and-Gas/circulars/amryt-admission-document.pdf Very exciting read. Still digesting, peer comparison of other companies in similar stages of orphan drug development at in the hundreds of millions to billions market cap range. Of course further funds will be required, this is a pharma company developing a drug for market. Management team have to be the best out there across all AIM pharma companies! Some very impressive reading. EIS approved too! This is one for the ISA/pension fund IMO think it could be life changing over the course of the next few years.
Several months ago the price was below 3p - What you glad about? Had you have sold today, you would have got 3.50p. I would be surprised if you could buy at 3p.. It bounced several times today at 3.07p. Let the market digest news, once this is stable then we will see it move on small volume. Google Harry Stratford. Massive hold & buy at these levels.
down a touch ? It converts at the price it closes at pre change so your talking out your...... Further more just reading ADVFN and i see you sold at 2.6p hoping to get back in lower....Not good form imo just buy back or don't.
as long as all goes to plan, it will move to 24p on the 19th april, then go from there on that day onwards buying at 3.1 today would mean at 24p you would be down a touch to begin with.